NT 227
Alternative Names: NT-227Latest Information Update: 28 Aug 2025
At a glance
- Originator Medical University of South Carolina
- Developer Medical University of South Carolina; Neuroene Therapeutics
- Class Antiparkinsonians; Small molecules; Vitamins
- Mechanism of Action Vitamin K replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for research development in Parkinson's-disease in USA (PO)
- 01 Jul 2021 Neuroene Therapeutics has patent protection for multiple analogues and the corresponding methods for multiple indications (Neuroene Therapeutics website, July 2021)
- 01 Jul 2021 Neuroene Therapeutics has patents pending for multiple analogues and the corresponding methods for multiple indications (Neuroene Therapeutics website, July 2021)